Role of Immunoglobulin A in Protection against Reovirus Entry into Murine Peyer's Patches

Silvey, Katherine J.; Hutchings, Amanda; Vajdy, Michael; Petzke, Mary M.; Neutra, Marian R.

doi:10.1128/jvi.75.22.10870-10879.2001

Cited by 72 publications

(75 citation statements)

References 58 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The finding that conversion of T1L virions to ISVPs is required for adherence to M cells in adult mice (2) leaves open the possibility that 1, 1, or 2, the viral proteins remaining on the particle surface after 3 removal, might mediate M cell attachment. We have recently shown that intragastric administration of the anti-1 MAb 5C6 prevents the entry of T1L ISVPs into murine Peyer's patches in vivo, whereas MAbs specific for 1 or 3 do not (61). This suggests, but does not prove, the importance of T1L 1 in binding to murine M cells.…”

Section: Discussionmentioning

confidence: 85%

The Viral σ1 Protein and Glycoconjugates Containing α2-3-Linked Sialic Acid Are Involved in Type 1 Reovirus Adherence to M Cell Apical Surfaces

Helander

Silvey

Mantis

et al. 2003

J Virol

Self Cite

View full text Add to dashboard Cite

Reovirus is a nonenveloped, 85-nm icosahedral pathogen that enters the mouse intestinal Peyer's patch mucosa by adhering to M cells and then exploiting the antigen-transporting activity of these specialized epithelial cells (2,50,73). When introduced into the intestinal lumens of adult mice, reovirus type 1 Lang (T1L) adheres to the apical surfaces of M cells but generally not to those of enterocytes, which cover the vast majority of the mucosa. It is known that T1L infection of the mouse mucosa in vivo requires proteolytic processing of the viral outer capsid by enzymes in the intestinal lumen (6, 9, 45). The resulting infectious subviral particles (ISVPs) have a cleaved form of the membrane penetration protein 1, have lost the 1-protecting protein 3, and may have the viral hemagglutinin 1 in a more extended conformation than that found in virions (18,20,38,44,45,48). We have previously shown that conversion of T1L virions to ISVPs is required for adherence to M cells in adult mice (2), but neither the T1L protein that mediates binding nor the M cell component recognized by that protein has been identified.The 1 protein serves as the viral adhesin that mediates hemagglutination (HA) and binding to several different types of cultured cells (3,

show abstract

Section: Discussionmentioning

confidence: 85%

The Viral σ1 Protein and Glycoconjugates Containing α2-3-Linked Sialic Acid Are Involved in Type 1 Reovirus Adherence to M Cell Apical Surfaces

Helander

Silvey

Mantis

et al. 2003

J Virol

Self Cite

View full text Add to dashboard Cite

show abstract

“…our desire to preserve the integrity of the rectal mucosal milieu. In this regard, it has been shown that while intestinal IgA does not seem to play a role in acute responses against retrovirus, it is important for memory responses against reinfection with the same virus (51). Moreover, it is well established that both oral live attenuated and inactivated poliovirus-based vaccines protect against poliomyelitis, even though the latter does not result in intestinal IgA responses.…”

Section: Discussionmentioning

confidence: 99%

Antibody-Mediated Protection against Mucosal Simian-Human Immunodeficiency Virus Challenge of Macaques Immunized with Alphavirus Replicon Particles and Boosted with Trimeric Envelope Glycoprotein in MF59 Adjuvant

Barnett

Burke

Sun

et al. 2010

J Virol

Self Cite

View full text Add to dashboard Cite

After more than 25 years of human immunodeficiency virus (HIV) research, a prophylactic vaccine able to control or prevent the worldwide spread of HIV/AIDS remains an elusive goal. Recent results in Thailand with the recombinant canary pox (ALVAC-HIV, vCP1521; Sanofi-Pasteur) prime-gp120 (AIDSVAX B/E) protein boost vaccine approach give us hope that such a vaccine is achievable (45). Nevertheless, the results from this trial as well as the disappointing outcome of the Step Study trial (7, 29, 46) vividly highlight the need to better understand the immune correlates of protection and the immune responses engendered by the diverse new vaccine technologies currently under evaluation (13,18,20,49). In the case of viral vectors, this is particularly critical, as the spectrum of immune responses elicited in animal models does not necessarily predict those eventually observed in human clinical trials and will require more thorough evaluations in order to identify the most predictive models. At the moment, nonhuman primate models, such as simian immunodeficiency virus (SIV) and simian-human immunodeficiency virus (SHIV) infection of macaques appear to be the most informative for guiding vaccine development (3,24,47,55), and more rigorous application of these models has begun to yield new and encouraging insights into protective immunity (5,19,27,56). Moreover, as most HIV transmissions occur through mucosal membranes, understanding the correlates of protection, following successful vaccinations, against mucosal challenge is of strong interest.Alphaviruses are positive-sense single-stranded 11.5-kb RNA viruses in the Togaviridae family. They are relatively simple enveloped viruses of approximately 60-nm diameter that have a cytoplasmic RNA-based life cycle and mature at the plasma membranes of infected cells. Recombinant alphavirus replicon particles used for vaccine applications are composed of a replicon vector that encodes the viral replicases (nonstructural proteins [NSPs]) and the vaccine antigen of interest and two packaging vectors that encode the major viral structural proteins (capsid and glycoproteins E1 and E2) required for particle formation. The chimeric (VEE/SIN) alpha-* Corresponding author. Mailing address: Novartis Vaccines and Diagnostics,

show abstract

“…IgG can be sufficient to protect mucosal surfaces where significant amounts of IgG, transudated from serum or produced locally, are normally present in secretions (Murphy 1999). In contrast, the reovirus-immunized IgA knockout mice did not have elevated antiviral IgG in intestinal secretions and were not protected against re-infection despite high levels of antireovirus IgG in serum (Silvey et al 2001). …”

Section: Discussionmentioning

confidence: 99%

Humoral intestinal immunity against Encephalitozoon cuniculi (Microsporidia) infection in mice

Sak¹,

Ditrich²

2005

FOLIA PARASIT

View full text Add to dashboard Cite

Abstract. Three strains of mice, BALB/c, IL-12 knock-out (KO) and INF-γ knock-out, were chosen as an experimental model for the study of intestinal immunity induction against Encephalitozoon cuniculi Levaditi, Nicolau et Schoen, 1923 infection. Mice were infected perorally with 10 7 spores and re-infected with the same dose 70 days after the first infection. The anti-E. cuniculi IgA, IgG and IgM responses in sera and extracts of stool samples were determined by ELISA. Results have shown specific antibody production in the sera and intestinal secretions of all three strains of mice induced orally by E. cuniculi spores. BALB/c mice developed a stronger humoral immune response than IL-12 KO mice. The lowest antibody response developed in INF-γ KO mice that succumbed to the infection within 28 days post infection.

show abstract

Role of Immunoglobulin A in Protection against Reovirus Entry into Murine Peyer's Patches

Cited by 72 publications

References 58 publications

The Viral σ1 Protein and Glycoconjugates Containing α2-3-Linked Sialic Acid Are Involved in Type 1 Reovirus Adherence to M Cell Apical Surfaces

The Viral σ1 Protein and Glycoconjugates Containing α2-3-Linked Sialic Acid Are Involved in Type 1 Reovirus Adherence to M Cell Apical Surfaces

Antibody-Mediated Protection against Mucosal Simian-Human Immunodeficiency Virus Challenge of Macaques Immunized with Alphavirus Replicon Particles and Boosted with Trimeric Envelope Glycoprotein in MF59 Adjuvant

Humoral intestinal immunity against Encephalitozoon cuniculi (Microsporidia) infection in mice

Contact Info

Product

Resources

About